Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The highest-paid CEOs in the corporate world, often act as guiding forces, leading their organizations toward growth and success. Their efforts are not just acknowledged with positions of power but ...

6. Leonard Schleifer (Regeneron Pharmaceuticals) – $452.9 Million Leonard Schleifer, CEO of Regeneron Pharmaceuticals, has overseen groundbreaking advancements in biopharmaceuticals. His $452.9 ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...

Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...

Leonard Schleifer for Regeneron Pharmaceuticals: $452.9 million Leonard Schleifer is the chief executive of Regeneron Pharmaceuticals, a biopharmaceutical company known for its innovative medicines.